Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document 62020CN0254

Case C-254/20: Request for a preliminary ruling from the Hof van beroep te Brussel (Belgium) lodged on 9 June 2020 — PI Pharma NV v Novartis AG, Novartis Pharma NV

OJ C 297, 7.9.2020, p. 29–30 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

7.9.2020   

EN

Official Journal of the European Union

C 297/29

Request for a preliminary ruling from the Hof van beroep te Brussel (Belgium) lodged on 9 June 2020 — PI Pharma NV v Novartis AG, Novartis Pharma NV

(Case C-254/20)

(2020/C 297/40)

Language of the case: Dutch

Referring court

Hof van beroep te Brussel

Parties to the main proceedings

Appellant: PI Pharma NV

Respondents: Novartis AG, Novartis Pharma NV

Questions referred

1.

Must Articles 34 to 36 TFEU be interpreted as meaning that, where a branded medicine (reference medicine) and a generic medicine have been put on the market in the EEA by economically linked undertakings, a trade mark proprietor’s opposition to the further commercialisation of the generic medicine by a parallel importer after the repackaging of that generic medicine by the affixing to it of the trade mark of the branded medicine (reference medicine) in the country of importation may lead to an artificial partitioning of the markets of the Member States?

2.

If the answer to that question is in the affirmative, must the trade mark proprietor’s opposition to that rebranding be assessed by reference to the BMS conditions?

3.

Is it relevant to the answer to those questions that the generic medicine and the branded medicine (reference medicine) are identical or have the same therapeutic effect as referred to in Article 3(2) of the Koninklijk besluit van 19 april 2001 inzake parallelinvoer (Royal Decree of 19 April 2001 on parallel imports)?
Top